# Adebrelimab Plus Cetuximab and Chemotherapy for Patients With RAS/BRAF Wild-Type Unresectable Liver Metastases Colorectal Cancer

> **NCT06231017** · PHASE2 · UNKNOWN · sponsor: **The First Affiliated Hospital of Zhengzhou University** · enrollment: 36 (estimated)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** Adebrelimab + Cetuximab+ Chemotherapy

## Key facts

- **NCT ID:** NCT06231017
- **Lead sponsor:** The First Affiliated Hospital of Zhengzhou University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-01-19
- **Primary completion:** 2025-01-19
- **Final completion:** 2026-01-19
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2024-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06231017

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06231017, "Adebrelimab Plus Cetuximab and Chemotherapy for Patients With RAS/BRAF Wild-Type Unresectable Liver Metastases Colorectal Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06231017. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*